A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of A Multi-Institutional Database

Yan, Tristan D. and Deraco, Marcello and Elias, Dominique and Glehen, Olivier and Levine, Edward A. and Moran, Brendan J. and Morris, David L. and Chua, Terence C. and Piso, Pompiliu and Sugarbaker, Paul H. (2011) A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of A Multi-Institutional Database. CANCER, 117 (9). pp. 1855-1863. ISSN 0008-543X, 1097-0142

Full text not available from this repository. (Request a copy)

Abstract

BACKGROUND: Currently, no tumor-node-metastasis (TNM) staging system exists for patients with diffuse malignant peritoneal mesothelioma (DMPM). The primary objective was to formulate a clinicopathological staging system through the identification of significant prognostic parameters. METHODS: Eight international institutions with prospectively collected data on patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy contributed to the registry. Two hundred ninety-four patients had complete clinicopathological data and formed the basis of this staging project. RESULTS: Peritoneal cancer index (PCI) was categorized into T-1 (PCI 1-10), T-2 (PCI 11-20), T-3 (PCI 21-30), and T-4 (PCI 30-39). Twenty-two patients had positive lymph nodes (N-1) and 12 patients had extra-abdominal metastases (M-1). The survival for patients with T-1 (PCI 1-10) N-0 M-0 was significantly superior to the other patients. This group of patients is therefore designated as Stage I. The survival of patients with T-2 (PCI 11-20) and T-3 (PCI 21-30), in absence of N-1 or M-1 disease, was similar. This group of patients was categorized as Stage II. The survival of patients with T-4 (PCI 30-39), N-1, and/or M-1 was similarly poor. This group of patients was therefore categorized as Stage III. Three prognostic factors were independently associated with survival in the multivariate analysis: histological subtype, completeness of cytoreduction, and the proposed TNM staging. The 5-year survival associated with Stage I, II, and III disease was 87%, 53%, and 29%, respectively. CONCLUSIONS: The proposed TNM staging system resulted in significant stratification of survival by stage when applied to the current multi-institutional registry data. Cancer 2011;117:1855-63. (C) 2010 American Cancer Society.

Item Type: Article
Uncontrolled Keywords: PERIOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; WOMEN; Peritoneal mesothelioma; cytoreductive surgery; peritonectomy; hyperthermic intraperitoneal chemotherapy
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Chirurgie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 22 Jun 2020 06:32
Last Modified: 22 Jun 2020 06:32
URI: https://pred.uni-regensburg.de/id/eprint/20893

Actions (login required)

View Item View Item